Experimental MASLD - Clinical
Nov
12
2023
Ballroom BC
-
Hynes Convention Center
11:00
AM
- 12:30 PM EST
Description
This session highlights clinical research advances in metabolic dysfunction-associated steatotic liver disease (MASLD). exploring the role of hepatic steatosis, fibrosis, and inflammation on MASLD.
Abstracts
- HEPATIC STEATOSIS IS ASSOCIATED WITH INCREASED CARDIOVASCULAR EVENT RATE AMONG PEOPLE AT LOW 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK
- PNPLA3 GENOTYPES ARE SIGNIFICANTLY ASSOCIATED WITH LIVER-RELATED OUTCOMES IN INDIVIDUALS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- ARTIFICIAL INTELLIGENCE TO MEASURE FIBROSIS CHANGE ON LIVER BIOPSY IN MAESTRO-MASH: A PHASE 3 SERIAL LIVER BIOPSY STUDY IN 966 PATIENTS WITH MASH TREATED WITH RESMETIROM OR PLACEBO
- HEPATIC LOBULAR INFLAMMATION IS THE MOST IMPACTED PROGNOSTIC FACTOR RATHER THAN FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN MASLD: MULTI-CENTER STUDY
- ADIPOSE TISSUE INSULIN RESISTANCE AFFECTS LIVER MITOCHONDRIAL FUNCTION INDEPENDENTLY OF LIVER FAT ACCUMULATION
- IDENTIFICATION OF THE ENVIRONMENTAL POLLUTANTS AND METABOLIC PATHWAYS ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE SEVERITY
Objectives
- Attendees will discuss new clinical research advances in MASLD.
- Discuss genetic, environmental, and metabolic contributions in MASLD.
- Participants will learn new tools to evaluate liver disease and prognosticate outcomes in MASLD.